Lonza builds large-scale high potency API plant

Published: 14-Jun-2007
Ingredients

Lonza plans to expand its capacity for the production of highly potent active pharmaceutical ingredients (APIs). The new manufacturing site will be built in Visp, Switzerland and enables the production of highly potent APIs on a large scale.


Lonza plans to expand its capacity for the production of highly potent active pharmaceutical ingredients (APIs). The new manufacturing site will be built in Visp, Switzerland and enables the production of highly potent APIs on a large scale.

Lonza says, as a result of this project it will be the sole custom manufacturer capable of handling large-scale manufacturing in this arena. This extension of the existing API-capacity in Visp is an important component of its strategy - called Lonza Exclusive Synthesis.

The company will invest more than CHF 80m (Euro 48m) in the construction of API-capacity and expects to have hired some 40 new employees by 2009 due to this investment. This capacity expansion will complement Lonza's existing smaller scale facilities for high potency APIs.

  • Companies:
  • Lonza
See more

You may also like

Ingredients

Staying ahead of the ADC curve

Read more
Even after the first antibody–drug conjugate (ADC) was approved in 2000 — Pfizer’s Mylotarg (gemtuzumab ozogamacin) — it took some time for these products to any make significant impact on the market. Now, though, the numbers have reached double figures, with many more ADC therapeutics currently working their way through the clinical pipeline, reports Charles Johnson, Senior Director, Commercial Development at Lonza Small Molecules

Trending Articles

  1. FDA makes groundbreaking decision to waive clinical efficiency studies for monoclonal antibody biosimilars The University of Illinois secured the first-ever FDA acceptance to waive clinical efficiency studies (CESs) for the biological drugs
  2. Rousselot Rousselot is a global leader of gelatin and collagen-based solutions, serving the food, health & nutrition, biomedical, and pharmaceutical sectors. With our advanced Science & Innovation team, we unlock the secrets of the collagen molecule to create products that meet the highest standards of safety and quality. Through our state-of-the-art operations and extensive technical and formulation expertise, we help our customers achieve their goals, create world-class products, and we “Reach further together”. Rousselot is Darling’s Ingredients Health Brand.
  3. Debunking the myths of HPMC adoption Adopting new products, formulations and ways of working can be a challenge for industries as regulated as pharmaceuticals, writes Dr Subhashis Chakraborty, General Manager, Head of Global Product Management, at ACG Capsules
  4. Lubrizol to showcase game-changing excipients and nutraceutical ingredients at CPHI Frankfurt Lubrizol partners with pharmaceutical and nutraceutical companies to develop innovative solutions that improve patient outcomes and offer consumer benefits
  5. Evonik increases plant-derived cholesterol supply The ingredient is used in the manufacture of mRNA vaccines and gene therapies

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Ingredients

Staying ahead of the ADC curve

Even after the first antibody–drug conjugate (ADC) was approved in 2000 — Pfizer’s Mylotarg (gemtuzumab ozogamacin) — it took some time for these products to any make significant impact on the market. Now, though, the numbers have reached double figures, with many more ADC therapeutics currently working their way through the clinical pipeline, reports Charles Johnson, Senior Director, Commercial Development at Lonza Small Molecules
Manufacturing

Lonza to support development of ovarian cancer drug

The CDMO will provide kilogram-scale synthesis, purification, and stability testing for Oasmia’s drug candidate
Manufacturing

Lonza expands stem cell offering for humanised mouse models

Humanised mice are used to explore how novel cancer biotherapies interact with a human-specific immune system
Manufacturing

Lonza to supply prequalified cells for CN Bio OOC technology

Organ-on-a-chip technology has the potential to solve the issues presented by 2D cell cultures and animal models, the companies say
Ingredients

Lonza announces cryopreserved Leukopak offering

Fresh Leukopaks can be hard to access and must be used rapidly to avoid cell degradation, limiting transportation options
Ingredients

Lonza introduces hi-res HLA-typed primary cell lots

This offering builds on the company’s human primary cell capabilities
Ingredients

The Lonza powder-in-capsule microdosing approach

Jeff Williamson and Ben Sahacic explain how microdosing offers a proven approach for biopharmaceutical companies to quickly assess new drug candidates while minimising API consumption
Subscribe now